Zusammenfassung
In einer multizentrischen europäischen Beobachtungsstudie (ECAS) mit über 15.000 Tumorpatienten wurden Prävalenz, Inzidenz und Therapieformen der tumorbedingten Anämie mit einem Hämoglobinwert von unter 10 g/dl untersucht. Deren Inzidenz betrug 53,7 %.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Aapro M, Scherhag A, Burger HU (2008) Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients.Br J Cancer.8;99(1): 14–22. Epub 2008 Jun 10
Auerbach M (2008) Should intravenous iron be the standard of care in oncology? J Clin Oncol. 26: 1579–1581
Bastit L, Vandebroek A, Altintas S et al. (2008) Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol. 1;26(10): 1611–1618
Bokemeyer C, Aapro MS, Courdi A et al. (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43(2): 258–270
Hedenus M, Birgegard G, Nasman P (2007) Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 21(4): 627–632
Henry DH, Dahl NV, Auerbach M et al. (2007) Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 12(2): 231–242
Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40(15): 2293–2306
Ludwig H, Pohl G (2006) Pathogenese und Therapie der therapie- und tumorbedingten Anamie. In: Schmoll HJ, Hoffken K, Possinger K (Hrsg.) Kompendium Internistische Onkologie, 4. Aufl. Heidelberg: Springer 2011–2024
Pedrazzoli P, Farris A, Del Prete S et al. (2008) Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 1;26(10): 1619–1625
Rizzo JD, Somerfield MR, Hagerty KL et al. (2008) Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 1;111(1): 25–41
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Retz, M., Gschwend, J. (2010). Behandlung der therapie- und tumorbedingten Anämie. In: Medikamentöse Tumortherapie in der Uroonkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-10381-0_9
Download citation
DOI: https://doi.org/10.1007/978-3-642-10381-0_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-10380-3
Online ISBN: 978-3-642-10381-0
eBook Packages: Medicine (German Language)